Interleukin-12 in anti-tumor immunity and immunotherapy
Top Cited Papers
- 1 April 2002
- journal article
- review article
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 13 (2), 155-168
- https://doi.org/10.1016/s1359-6101(01)00032-6
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell CarcinomaJournal of Interferon & Cytokine Research, 2001
- Tamoxifen for the prevention of breast cancer: Pro:European Journal Of Cancer, 2000
- Interleukin-12 as an Adjuvant for Cancer ImmunotherapyMethods, 1999
- Impairment of Mycobacterial Immunity in Human Interleukin-12 Receptor DeficiencyScience, 1998
- THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune ResponsesAnnual Review of Immunology, 1998
- IL-12 as an adjuvant for cell-mediated immunitySeminars in Immunology, 1997
- Cytokines, tumour-cell death and immunogenicity: a question of choiceImmunology Today, 1997
- Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonistEuropean Journal of Immunology, 1995
- CD4 T cells inhibitin vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genesEuropean Journal of Immunology, 1995
- Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.The Journal of Experimental Medicine, 1992